Developmental Therapeutics Committee
The Development Therapeutics Committee, led by Keith T. Flaherty, MD, is in a unique position to facilitate the creation of new types of cancer treatment trials that personalize therapy using predictive biomarkers and drug targets. Its role in the Group is to:
- Educate members about new treatments, drug targets, and biomarker technologies
- Provide a platform for disseminating scientific concepts that arise within the 12 cancer-type-oriented committees and working groups in the Therapeutic Studies Program
- Conduct correlative studies that explore variability in patients and tumors, with a treatment focus rather than a disease focus
The original concept for the landmark NCI-MATCH precision medicine cancer trial originated here, and this committee is co-leading the trial with researchers at the National Cancer Institute.
Phase I experts, clinical and laboratory-based translational investigators, pathology and imaging experts, and leaders from the National Cancer Institute's Specialized Programs of Research Excellence (SPORES) participate in the Developmental Therapeutics Committee to maximize awareness of emerging, cutting-edge therapies. The committee also includes investigators associated with the National Cancer Institute's Experimental Therapeutics Clinical Trials Network (NCI ETCTN), early-career members, and researchers with broad experience in conducting industry-sponsored trials.
Dual committee membership in the Therapeutics Studies Program committees ensures two-way communication between clinical and early-phase trial investigators about emerging therapeutic concepts and biomarker strategies.